AU2016258001B2 - Injectable depot formulations - Google Patents

Injectable depot formulations Download PDF

Info

Publication number
AU2016258001B2
AU2016258001B2 AU2016258001A AU2016258001A AU2016258001B2 AU 2016258001 B2 AU2016258001 B2 AU 2016258001B2 AU 2016258001 A AU2016258001 A AU 2016258001A AU 2016258001 A AU2016258001 A AU 2016258001A AU 2016258001 B2 AU2016258001 B2 AU 2016258001B2
Authority
AU
Australia
Prior art keywords
kinase inhibitor
subject
injectable composition
sustained release
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016258001A
Other languages
English (en)
Other versions
AU2016258001A1 (en
Inventor
Paul Ashton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Eyepoint Pharmaceuticals US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals US Inc filed Critical Eyepoint Pharmaceuticals US Inc
Publication of AU2016258001A1 publication Critical patent/AU2016258001A1/en
Assigned to EYEPOINT PHARMACEUTICALS US, INC. reassignment EYEPOINT PHARMACEUTICALS US, INC. Amend patent request/document other than specification (104) Assignors: PSIVIDA US, INC.
Application granted granted Critical
Publication of AU2016258001B2 publication Critical patent/AU2016258001B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016258001A 2015-05-05 2016-05-05 Injectable depot formulations Active AU2016258001B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157257P 2015-05-05 2015-05-05
US62/157,257 2015-05-05
PCT/US2016/030912 WO2016179357A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Publications (2)

Publication Number Publication Date
AU2016258001A1 AU2016258001A1 (en) 2017-11-09
AU2016258001B2 true AU2016258001B2 (en) 2020-06-04

Family

ID=57218334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016258001A Active AU2016258001B2 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Country Status (10)

Country Link
US (1) US20160324836A1 (enExample)
EP (1) EP3291812B1 (enExample)
JP (1) JP2018520093A (enExample)
CN (1) CN107530334A (enExample)
AU (1) AU2016258001B2 (enExample)
BR (1) BR112017023762A2 (enExample)
CA (1) CA2984637A1 (enExample)
MX (1) MX385405B (enExample)
RU (1) RU2017137763A (enExample)
WO (1) WO2016179357A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
CN114245737A (zh) * 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090666A1 (en) * 2011-12-14 2013-06-20 Abbvie Inc. Compositions containing kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101890018B (zh) * 2009-05-22 2014-06-18 中国科学院化学研究所 一种酪氨酸蛋白激酶抑制剂及其制备方法
WO2013000909A1 (en) * 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
CN104204804B (zh) * 2011-11-11 2016-09-28 因特利凯有限责任公司 激酶抑制剂的组合及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090666A1 (en) * 2011-12-14 2013-06-20 Abbvie Inc. Compositions containing kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILD A.T. ET AL., "Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma", PLOS ONE, (2013-06), vol. 8, no. 6, pages 1 - 13 *

Also Published As

Publication number Publication date
WO2016179357A1 (en) 2016-11-10
EP3291812A4 (en) 2019-01-09
MX2017014084A (es) 2018-06-20
MX385405B (es) 2025-03-18
CA2984637A1 (en) 2016-11-10
US20160324836A1 (en) 2016-11-10
EP3291812B1 (en) 2021-09-01
CN107530334A (zh) 2018-01-02
BR112017023762A2 (pt) 2018-07-31
RU2017137763A (ru) 2019-06-05
EP3291812A1 (en) 2018-03-14
AU2016258001A1 (en) 2017-11-09
JP2018520093A (ja) 2018-07-26
RU2017137763A3 (enExample) 2019-08-21

Similar Documents

Publication Publication Date Title
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
AU2022202629B2 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
AU2016258001B2 (en) Injectable depot formulations
US10617735B2 (en) Methods and compositions for preserving retinal ganglion cells
DK1848431T3 (en) LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
KR20160135372A (ko) 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
BRPI0709016A2 (pt) formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
JP2010536797A5 (enExample)
KR20100055482A (ko) 안질환 또는 안이상의 치료를 위한 제제
CN102695511A (zh) 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途
TWI731853B (zh) 徐放性醫藥組成物及其安定化方法
JP6598381B2 (ja) 角膜厚調節剤
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
US20180009758A1 (en) Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
KR20100051811A (ko) 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제
US20160376239A1 (en) N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
CN115867264A (zh) 局部眼科组合物和治疗异常血管新生的方法
US10464902B1 (en) Multi-tyrosine kinase inhibitors derivatives and methods of use
RU2623205C1 (ru) Офтальмологический гель таурина
RU2732407C1 (ru) Фармацевтическая композиция, содержащая палоносетрон в качестве активного ингредиента
US10899712B2 (en) Multi-tyrosine kinase inhibitors derivatives and methods of use
Gupta et al. Antivascular Endothelial Growth Factor Agents
JPWO2000043015A1 (ja) 点眼用液剤

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: EYEPOINT PHARMACEUTICALS US, INC.

Free format text: FORMER NAME(S): PSIVIDA US, INC.

FGA Letters patent sealed or granted (standard patent)